Baricitinib versus Tocilizumab in Critically Ill COVID-19 Patients: A Retrospective Cohort Study
Description
CONCLUSIONS: Baricitinib use was associated with better WHO-CPS scores at day 14 and day 7 compared with tocilizumab in a cohort of critically ill patients with COVID-19. The odds of having a one unit increase in WHO-CPS score at day 14 was 71%
